OncoZenge
5.94
SEK
-3.73 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-3.73%
-4.81%
+58.4%
+58.4%
-7.04%
+74.71%
-33.18%
-
-51.46%
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Read moreMarket cap
69.58M SEK
Turnover
95.22K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
15.5
2025
Interim report Q1'25
28.5
2025
General meeting '25
21.8
2025
Interim report Q2'25
All
Press releases
ShowingAll content types
OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge™
OncoZenge AB: OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools